Health Care

Merck’s EMA win for WINREVAIR and Guggenheim’s price upgrade boost investor confidence in the drug’s PAH expansion and the company’s future earnings growth.

Hologic Inc. faces a regulatory investigation that could affect share value, liquidity, and its medical‑device pipeline—shareholders and clinicians urged to monitor filings and stay informed.

Intuitive Surgical’s FDA clearances for the da Vinci Single‑Port system—hernias, cholecystectomy, appendectomy—boost its market reach, drive $180 M+ revenue, and set the stage for AI‑enabled data analytics and global expansion.

Explore how Astellas’ new GI oncology data and market strategy can drive growth in gastric cancer treatment and broader therapeutic segments.

Genmab’s €400 m acquisition of Merus adds petosemtamab, a Breakthrough Therapy bispecific antibody for head‑and‑neck cancer, boosting its oncology pipeline and potential revenue.

GSK’s latest EU and US approvals—depemokimab, Nucala, Arexvy, Blujepa—show how pricing, reimbursement and supply‑chain agility drive commercial success in respiratory and infectious disease markets.

Elevance Health strengthens governance with former Pfizer counsel Amy Schulman on its board, boosting audit and finance oversight while expanding community maternal‑health initiatives and positioning for growth in the U.S. health‑insurance market.

Insmed’s breakthrough PARP‑inhibitor Brinsupri shows 32% response rates and improved quality‑of‑life in platinum‑resistant ovarian cancer, sparking new investor interest and a fast‑track FDA review.

Waters Corp. gains “Outperform” upgrades and bullish RSI as its LC‑MS innovations, FDA clearance, and strategic biopharma partnership boost investor confidence.

Solventum Corp’s new technical momentum, governance upgrades, and crypto trading launch boost its appeal to investors seeking advanced composite growth in the energy transition.